Warning: The NCBI web site requires JavaScript to function. more...
Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.
Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS.
Breast Cancer Res. 2005;7(5):R765-74. Epub 2005 Jul 27.
Related citations
Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells.
Lee K, Wang T, Paszczynski AJ, Daoud SS.
Biochem Biophys Res Commun. 2006 Oct 27;349(3):1117-24. Epub 2006 Sep 5.
PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y, Besch-Williford C, Hyder SM.
Int J Oncol. 2009 Nov;35(5):1015-23.
PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
Wang T, Lee K, Rehman A, Daoud SS.
Biochem Biophys Res Commun. 2007 Jan 5;352(1):203-12. Epub 2006 Nov 9.
Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM.
Endocr Relat Cancer. 2009 Mar;16(1):85-98. Epub 2008 Dec 15.
Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation.
Perotti C, Liu R, Parusel CT, Böcher N, Schultz J, Bork P, Pfitzner E, Groner B, Shemanko CS.
Breast Cancer Res. 2008;10(6):R94. Epub 2008 Nov 13.
Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
Liang Y, Besch-Williford C, Benakanakere I, Hyder SM.
Int J Oncol. 2007 Oct;31(4):777-84.
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM.
Breast Cancer Res Treat. 2011 Jan;125(2):407-20. Epub 2010 Mar 27.
PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.
Russo D, Ottaggio L, Penna I, Foggetti G, Fronza G, Inga A, Menichini P.
Biochem Biophys Res Commun. 2010 Nov 12;402(2):345-50. Epub 2010 Oct 12.
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ.
Cancer Cell. 2009 May 5;15(5):376-88.
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
Li Y, Mao Y, Brandt-Rauf PW, Williams AC, Fine RL.
Mol Cancer Ther. 2005 Jun;4(6):901-9.
In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.
Shi H, Lambert JM, Hautefeuille A, Bykov VJ, Wiman KG, Hainaut P, de Fromentel CC.
Carcinogenesis. 2008 Jul;29(7):1428-34. Epub 2007 Nov 28.
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G.
Nat Med. 2002 Mar;8(3):282-8.
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Robles AI, Wright MH, Gandhi B, Feis SS, Hanigan CL, Wiestner A, Varticovski L.
Clin Cancer Res. 2006 Nov 1;12(21):6547-56.
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.
Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C, Merup M.
Br J Haematol. 2004 Nov;127(3):285-91.
PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins.
Rökaeus N, Klein G, Wiman KG, Szekely L, Mattsson K.
Oncogene. 2007 Feb 15;26(7):982-92. Epub 2006 Aug 14.
[Effect of HSP90 function inhibited on the telomerase and P53 mutant in breast cancer cells].
Li X, Deng HY.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Mar;39(2):181-3. Chinese.
PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells.
Magrini R, Russo D, Ottaggio L, Fronza G, Inga A, Menichini P.
J Cell Biochem. 2008 Aug 15;104(6):2363-73.
The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.
Farnebo M, Bykov VJ, Wiman KG.
Biochem Biophys Res Commun. 2010 May 21;396(1):85-9. Review.
p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y, Wu J, Stancel GM, Hyder SM.
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):173-82. Epub 2005 Jan 28.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on